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Abstract 1 
Context: The investigation of dose-response associations between carbohydrates, 2 
glycemic index (GI), glycemic load (GL) and risk of breast cancer stratified by 3 
menopausal status, hormone receptor status and body mass index (BMI) remains 4 
inconclusive.  5 
Objective: A systematic review and dose-response meta-analyses was conducted to 6 
investigate these associations.  7 
Data sources: As part of the World Cancer Research Fund/American Institute for 8 
Cancer Research Continuous Update Project, we searched PubMed for relevant 9 
studies on these associations, up to May 2015. 10 
Study selection: Prospective studies reporting associations on intake of 11 
carbohydrates, GI, GL and breast cancer risk were included.  12 
Data extraction: Two investigators independently extracted data from included 13 
studies. 14 
Data synthesis: Random-effects models were used to summarize relative risks (RRs) 15 
and 95% confidence intervals (CIs). Heterogeneity between subgroups, including 16 
menopausal status, hormone receptor status and body mass index (BMI) was 17 
explored using meta-regression. Nineteen publications were included. The summary 18 
RRs (95%CIs) for breast cancer were 1.04 (1.00-1.07) per 10 units/d for GI, 1.01 (0.98-19 
1.04) per 50units/d for GL, and 1.00 (0.96-1.05) per 50g/d for carbohydrates, 20 
respectively. For GI, the association appeared slightly stronger among 21 
postmenopausal [summary RR (95%CI): 1.06 (1.02-1.10) per 10units/d)] than 22 
premenopausal women, though the difference was not statistically significant 23 
(pheterogeneity=0.15). GL and carbohydrates were positively associated with breast 24 
cancer among postmenopausal women with estrogen-negative tumours [summary 25 
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RRs (95%CIs): 1.28 (1.08-1.52) for GL and 1.13 (1.02-1.25) for carbohydrates)]. No 26 
differences in BMI were detected.  27 
Conclusions: Menopausal and hormone receptor status, but not BMI might be 28 
potential influencing factors for the associations between carbohydrates, GI, GL and 29 
breast cancer. 30 
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Introduction 31 
Breast cancer is the most common cancer among women worldwide with an 32 
estimated 1.67 million new cancer cases diagnosed in 2012.1 Many risk factors have 33 
been identified, including older age, hormonal and reproductive factors, and modifiable 34 
lifestyle factors.2-4 Evidence is available that obesity, type 2 diabetes and possibly 35 
insulin resistance are related to increased risk of postmenopausal breast cancer as 36 
well.4-8  37 
Thus, recently, there has been growing interest in the association between 38 
intake of foods related to glucose and insulin metabolism, and risk of breast cancer. 39 
Studies investigating the association between intake of total carbohydrates, or specific 40 
types of carbohydrates (such as total sugars or specific sugars), and breast cancer 41 
reported contradicting results,9-21 and so far, no meta-analysis on this topic is 42 
available. Furthermore, it has been shown that the effect of different carbohydrates on 43 
post-prandial blood sugar concentration varies. Several meta-analyses investigated 44 
the association between diets with high glycemic index (GI) and glycemic load (GL) ± 45 
markers of carbohydrate quality ± and risk of breast cancer.22-28 While findings of some 46 
meta-analyses indicated that breast cancer risk was moderately increased for GI 22, 25, 47 
26
 and GL 24, other studies failed to reach statistical significance for GI 23, 24, 27, 28 or 48 
GL,22, 23, 25-28 respectively.  49 
These studies have performed high versus low meta-analysis and little is known 50 
about the dose-response relation between GI, GL and breast cancer risk. Furthermore, 51 
studies that have stratified their analyses by menopausal status did not report 52 
differences for GI for pre- and postmenopausal women, whereas the association for 53 
GL and breast cancer seemed to be stronger in premenopausal women than in 54 
postmenopausal women.23, 25, 26, 28 Only the most recent meta-analysis investigated 55 
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the associations between GI, GL and breast cancer stratified by estrogen-receptor 56 
(ER) status of the tumor and indicated a potential positive association only in women 57 
with estrogen-receptor-negative (ER-) status,28 whereas evidence on stratification by 58 
other hormone receptor status, such as progesterone receptors (PR) is lacking. In 59 
addition, that most recent meta-analysis did not include the cohorts of the National 60 
Institutes of Health-American Association of Retired Persons Diet and Health Study 61 
(NIH-AARP),29 WKH:RPHQ¶VKHDOWKVWXG\:+6,30 and did not include the most recent 62 
UHSRUWV ZLWK XSGDWHG LQIRUPDWLRQ RI WKH 1XUVHV¶ +HDOWK 6WXG\ 1+S) II,17 and the 63 
European Prospective Investigation into Cancer and Nutrition (EPIC) study.16 64 
Moreover, controversial findings have been reported by individual studies whether 65 
excess body weight as measured by body mass index (BMI) influences the 66 
carbohydrate-, GI-, or GL-breast cancer associations.12, 13, 15, 17, 31 But so far, evidence 67 
is lacking that summarize these findings.  68 
Therefore, our aims were twofold. First, we performed a systematic review and 69 
dose-response meta-analysis of prospective studies to investigate the shape and the 70 
magnitude of the associations between dietary factors related to glucose metabolism, 71 
including intake of carbohydrates, GI, GL, and specific types of carbohydrates and risk 72 
of breast cancer. Second, we investigated whether these associations differed by 73 
menopausal status, hormone receptor status and BMI, respectively. 74 
 75 
Methods 76 
This report was conducted according to the Preferred Reporting Items for Systematic 77 
Reviews and Meta-Analyses (PRISMA) statement.32 78 
 79 
Search strategy 80 
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Several databases, including, PubMed, Embase, CAB Abstracts, ISI Web of 81 
Science, BIOSIS, Latin American and Caribbean Center on Health Sciences 82 
Information, Cochrane library, Cumulative Index to Nursing and Allied Health 83 
Literature, The Allied and Complementary Medicine Database, National Research 84 
Register and In Process Medline, were searched up to December 2005 by several 85 
reviewers at Istituto Nazionale Tumori, Milan for the WCRF/AICR Second Expert 86 
Report (http://wcrf.org/int/research-we-fund/continuous-update-project-cup). All the 87 
relevant prospective studies were identified by the PubMed searches and therefore a 88 
change in the protocol was made and only PubMed was used for the updated searches 89 
from January 2006 up to May 2015. The literature search was carried out following a 90 
predefined protocol, which includes all the details of the search terms and has been 91 
published online 92 
(http://www.wcrf.org/sites/default/files/protocol_breast_cancer_2008.pdf). Reference 93 
lists of relevant papers and reviews were hand-searched to identify any other 94 
potentially relevant papers.  95 
 96 
Study selection 97 
The PICOS (Participants, Intervention Comparators, Outcomes, Study Design) 98 
criteria are presented in Table 1. The criteria for inclusion were as follows: I) 99 
investigation of the association between dietary intake of carbohydrates, GI, GL, 100 
specific types of carbohydrates (total and specific sugars, including fructose, sucrose, 101 
glucose, lactose, maltose and added sugars), and incidence of breast cancer, II) 102 
prospective study design, including cohort, case-cohort, or nested case-control 103 
studies, as well as follow-up studies of randomized clinical trials, and III) reported 104 
adjusted risk estimates (including relative risk (RR), hazard ratio (HR), or odds ratio 105 
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(OR) and the corresponding 95% confidence intervals (CIs)) for the association 106 
between carbohydrates, GI, GL or specific types of carbohydrates (total and specific 107 
sugars), and breast cancers. If multiple articles were published for the same study, we 108 
included the newest publication providing the largest number of cases. Two studies 109 
were only included in subgroups analyses.33, 34 Studies were excluded if they did not 110 
provide enough data on the exposure (no quantification of the exposure were reported 111 
or only high vs. low analyses were shown),35-39 or they assessed GI, GL or 112 
carbohydrates in childhood or adolescence.40, 41 113 
 114 
Data extraction 115 
The following information were extracted ILUVW DXWKRU¶V ODVW QDPH \HDU RI116 
publication, country where the study was conducted, study name, study design, age, 117 
specific characteristics of the study population, study size, number of cases, duration 118 
of follow-up, dietary assessment method, exposure (carbohydrates, GI, GL, total and 119 
specific sugars), quantity of intake, RRs and 95% CIs from the models with most 120 
number of confounder adjustments, and variables adjusted for in analyses.  121 
 122 
Statistical methods 123 
 We conducted dose-response meta-analyses to summarize the association 124 
between carbohydrates, GI, GL, specific sugars, and breast cancer, by using random-125 
effects models.42 The linear dose-response trends (when not provided) were 126 
computed from the natural logarithm of the RRs and 95% CI across categories of 127 
intake of carbohydrates, specific sugars, GI, or GL, respectively, using the method by 128 
Greenland and Longnecker.43 This method requires information on the RR with the 129 
respective 95% CI, the distribution of cases, person-years or non-cases, and the 130 
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quantified exposure value for at least three exposure categories. For studies that did 131 
not report on cases or persons-years/ non-cases per category, the total numbers were 132 
divided by the number of quantiles. For example, when the total number of person-133 
years was reported, and the exposure was expressed as quintiles, the total number of 134 
person-years was divided by five. Means or medians of intake were assigned to each 135 
category. When only the range of the category was reported, we estimated the 136 
midpoint between the lower and upper limit. When a category was open-ended 137 
(uppermost or lowermost intake categories), we assumed that the range was the same 138 
as the adjacent category. When studies reported dietary intake as g/1000 kcal/d or % 139 
of energy/d, we converted the intake into g/d if appropriate information was available 140 
in the study.17, 18 Based on previous reports, the summary RRs of the dose-response 141 
meta-analyses are presented for an increment per 50 g/d for carbohydrates,44 10 142 
units/d for GI,45 50 units/d for GL,45 and 10 g/d for sugar, or specific sugar,20 143 
respectively. We investigated whether there was a non-linear dose-response relation 144 
between carbohydrates, GI, GL, specific carbohydrates, and breast cancer risk using 145 
restricted cubic spline regression models with three knots at the 10th, 50th and 90th 146 
percentile, and a likelihood ratio test was used to evaluate non-linearity.46, 47  147 
First, we examined the dietary factors with breast cancer risk (any, pre-, and 148 
postmenopausal breast cancer). We combined an overall RR for studies that reported 149 
findings separately for pre- and postmenopausal women using fixed-effect meta-150 
analysis. Most studies have assessed premenopausal status only once (at baseline). 151 
Thus, we also stratified the analyses among premenopausal women by the time of 152 
assessment of premenopausal status (assessed at exposure vs. assessed at breast 153 
cancer diagnosis). Second, we stratified our meta-analyses by hormone receptor 154 
status, including ER (ER+ and ER-), PR (PR+ and PR-), and combinations of ER and 155 
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PR because it has been suggested that risk associations between carbohydrates, GI, 156 
GL and breast cancer might vary between this different tumour types. 7KH+DPOLQJ¶V157 
methods was used to combine RRs (95% CI) for different subtypes if required.48 For 158 
example, when a study reported on the combination of hormone receptor status only 159 
(ER+/PR+ and ER+/PR-), we combined the two individual estimates to one single 160 
estimate (ER+). We performed these analyses for all breast cancers and among 161 
postmenopausal women, information among premenopausal women was limited. 162 
Third, we investigated whether excess body weight may influence the association 163 
between carbohydrates, GI, GL and breast cancer (all, and pre- and postmenopausal 164 
breast cancer separately) by stratifying the analyses E\%0,YVNJP2), as 165 
defined by the studies. Therefore, we included the study by Lajous et al. (E3N, the 166 
French cohort in EPIC)33 because stratified analysis by BMI for the associations 167 
between carbohydrates, GI, GL and breast cancer were not available in the total EPIC 168 
cohort.16  169 
Heterogeneity between studies was evaluated by the percentage of total 170 
variation in risk estimates explained by between-study variation (I2 statistics).49 171 
Sources of heterogeneity were explored by subgroup analyses, including geographic 172 
area (Europe, North America, Asia-Pacific), duration of follow-up (<10 \  \, 173 
number of cases , reference food for measuring GI and GL (glucose, 174 
white bread, combination of glucose and white bread), and adjustment for possible 175 
confounders, including hormone replacement therapy (HRT) use, parity, age at first 176 
birth, age at menopause, age at menarche, oral contraceptive use, education, physical 177 
activity, smoking, alcohol intake, family history of breast cancer, and history of breast 178 
disease. All the studies included in our meta-analysis adjusted for age, BMI and total 179 
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energy intake. Differences between subgroups were assessed using meta-regression 180 
analysis.49 181 
Publication bias was visually explored by checking funnel plots for asymmetry 182 
DQGE\DSSO\LQJ(JJHU¶VWHVW50 183 
A two-tailed p-value of <0.05 was considered as statistical significant. All 184 
analyses were performed using Stata 13.0 software (StataCorp, College Station, TX, 185 
USA).  186 
 187 
Results 188 
We identified 15 prospective studies (19 publications) on carbohydrates, GI, 189 
GL, total sugar and/or fructose intake and risk of breast cancer (Figure 1 and Table 190 
2). Out of these studies, ten studies were from Northern America, four from Europe 191 
and one from Asia-Pacific (Table 2).  192 
 193 
Carbohydrates  194 
In total, eleven prospective studies were included in the dose-response meta-195 
analysis on carbohydrates (range: 112.3-343.5 g/d) and risk of breast cancer, 196 
including 30,275 cases among 892,403 participants.9-17, 19, 21 There was no evidence 197 
of an association between intake of carbohydrates and risk of breast cancer [summary 198 
RR (95% CI) per 50 g/d: 1.00 (0.96-1.05); Figure 2A]. Statistically significant 199 
heterogeneity was observed between the studies (I2=57% and pheterogeneity=0.01), 200 
mainly driven by some smaller and earlier studies.9-11, 21 No significant associations 201 
were observed in pre- and postmenopausal women (Figure 2B and Table 3). In total, 202 
four studies reported on the association between carbohydrates and breast cancer 203 
stratified by hormone receptor status.15, 16, 19, 34 Carbohydrate intake was positively 204 
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associated to increased risk of ER- breast cancers [summary RR (95% CI) per 50 g/d: 205 
1.11 (1.02-1.21); Table 3 but not with ER+ breast cancer (pheterogeneity between ER- and 206 
ER+ receptor types=0.03). The same pattern was observed when the analysis was 207 
restricted to postmenopausal women only (Table 3).  208 
Among the three studies stratified the results by BMI,12, 14, 33 we found no 209 
significant heterogeneity between normal and overweight women (pheterogeneity between 210 
BMI<25 and %0,NJP2=0.32; Table 3).  211 
In further subgroup analyses, neither geographic area, duration of follow-up, 212 
number of cases, nor adjustment for confounders modified the association between 213 
carbohydrates and breast cancer (Table 3 and Supplemental Table 2).  214 
There was statistical indication of a non-linear relation between carbohydrates 215 
intake and risk of breast cancer, however associations were weak (pnon-linearity=0.02; 216 
Figure 2C). There was no statistical HYLGHQFH RI SXEOLFDWLRQ ELDV (JJHU¶V WHVW217 
p=0.99). The funnel plot shows a small study reporting a strong positive association,11 218 
and two small studies reporting strong inverse associations (Supplemental Figure 219 
1A).9, 21 220 
 221 
Glycemic index 222 
We identified ten studies that were eligible for dose-response meta-analysis on 223 
dietary GI (range 47.8-98.0 units/d) and risk of breast cancer, including 36,900 cases 224 
among 1,102,422 women.12-17, 19, 29, 51, 52 Out of these, five studies used glucose,14, 17, 225 
19, 29, 51
 three studies white bread,12, 15, 52 and two studies glucose and white bread13, 16 226 
as reference food for the calculation of GI.  227 
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The summary RR (95% CI) per 10 units GI/d was 1.04 (95% CI: 1.00±1.07), 228 
with no statistically significant heterogeneity between the studies (I2=27%; 229 
pheterogeneity=0.19) (Figure 3A).  230 
The association between GI and breast cancer was statistically significant in 231 
postmenopausal [summary RR (95%CI): 1.06 (1.02-1.10)], but not in premenopausal 232 
women [summary RR (95%CI): 1.01 (0.93-1.10)] (Figure 3B). However, this 233 
difference was not statistically significant (p=0.15) (Table 3). There was no evidence 234 
of heterogeneity between timing of assessment of premenopausal status (assessed 235 
at exposure vs. at diagnosis: pheterogeneity=0.50; Table 3).  236 
In total, only four studies investigated the association between GI and risk of 237 
breast cancer stratified by hormonal receptor status.15-17, 19 In our meta-analysis no 238 
clear pattern emerged. A positive association was observed for ER+/PR- breast 239 
cancer, but the association was not statistically significant [summary RR (95%CI): 1.29 240 
(0.96-1.73)] and there was no statistically significant difference between the subgroups 241 
(pheterogeneity=0.20) (Table 3). For postmenopausal breast cancer, the association was 242 
slightly stronger for ER- and/or PR- breast cancers, but findings were not significant 243 
and no statistically significant differences between the subgroups were detected 244 
(Table 3).  245 
Overall five studies examined the association between GI and breast cancer 246 
stratified by BMI.12, 13, 17, 33, 51 There was no evidence of a difference by BMI, overall or 247 
among pre- and postmenopausal women (Table 3). In addition, five other studies 248 
reported that the association between GI and breast cancer was not modified by BMI 249 
(data not shown in the publications).15, 16, 19, 29, 52  250 
When we stratified our meta-analysis by geographic area, duration of follow-251 
up, number of cases or assessment of GI, we did not detect any differences by strata 252 
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(Table 3). In addition, we examined whether the inclusion of important confounders 253 
could affect our results, but findings did not change substantially (Supplemental 254 
Table 2).     255 
There was no evidence for a non-linear association between GI and breast 256 
cancer risk (pnon-linearity= 0.32; Figure 3C). The curve showed a significant increase of 257 
breast cancer risk with increasing units of GI. There was no statistical evidence of 258 
SXEOLFDWLRQELDV(JJHU¶VWHVWS 7), but the funnel plot shows asymmetry driven by 259 
one small study51 (Supplemental Figure 1B). 260 
 261 
Glycemic load 262 
We included eleven studies, based on 37,846 cases among 1,140,868 women, 263 
investigating the association between GL (range: 52.9-239.4 units/d) and breast 264 
cancer in our dose-response meta-analysis.12, 13, 15-17, 19, 29, 30, 51-53 Six studies used 265 
glucose,14, 17, 19, 29, 30, 51 three studies white bread,12, 15, 52 and two studies glucose and 266 
white bread13, 16 as reference food for the calculation of GI.  267 
Overall, there was no association between GL and breast cancer [summary RR 268 
(95% CI) per 50 units/d: 1.01 (95% CI: 0.98±1.04)]. There was suggestion of 269 
heterogeneity between the studies (I2=43%; pheterogeneity = 0.07) (Figure 4A).  270 
 There was no evidence of differences by menopausal status (Figure 4B and 271 
Table 3), or by timing of assessment of premenopausal status (Table 3). After 272 
stratification by hormonal receptor status (n=3 studies)15, 16, 19, GL became a 273 
statistically significant risk factor for breast cancer among women with ER-, or ER-274 
/PR- tumours [summary RR (95% CI) per 50 units/d: 1.20 (95% CI: 1.05-1.38), or 1.19 275 
(95% CI: 1.02-1.38), respectively; Table 3]. Statistically significant differences 276 
between postmenopausal women with ER- compared to ER+ tumours were observed 277 
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[summary RR (95% CI) per 50 units/d: 1.28 (95% CI: 1.08±1.52), pheterogeneity between 278 
ER- and ER+ receptor types=0.05; Table 3].  279 
Six studies reported associations stratified by BMI,12, 13, 15, 17, 33, 51 and no 280 
differences by BMI were detected (Table 3). In four other studies there was no 281 
modification by BMI level (data not shown in the publications), 16, 19, 29, 30, 52 . One study 282 
found an increased risk of breast cancer in women with a BMI <25 kg/m2 [RR (95% 283 
/CI) for the highest versus lowest quintile of GL: 1.26 (1.06-1.50)], but not in women 284 
with a BMI 25 kg/m2 [RR (95%CI): 1.08 (0.88-1.33)].15   285 
We did not observe any differences between geographic areas, duration of 286 
follow-up, number of cases and assessment of GL (Table 3). In addition, no 287 
differences between studies adjusting or not adjusting for main confounders were 288 
present (Supplemental Table 2).    289 
There was indication of a non-linear association between GL and breast cancer 290 
risk (pnon-linearity=0.04; Supplemental Figure 4C), indicating no association at low score 291 
levels and positive association from GL values above approximately 150 units/d. There 292 
ZDVQRVWDWLVWLFDOHYLGHQFHRISXEOLFDWLRQELDV(JJHU¶VWHVWS ); the funnel plot 293 
shows asymmetry driven by one study51 (Supplemental Figure 1C).  294 
 295 
Sugars 296 
We identified four studies, including 12,414 breast cancer cases among 297 
384,651 participants, on total sugar intake (defined as intrinsic sugars; range: 44.5-298 
155.4 g/d) and risk of breast cancer.13, 18, 19, 21 The summary RR per 10g /d was 0.99 299 
(0.98-1.01, I2=53%, pheterogeneity=0.10) (Figure 5A), and no indication of a non-linear 300 
relation between sugar intake and risk of breast cancer was observed (pnon-linearity=0.24; 301 
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Figure 5B). 7KHUHZDVQRVWDWLVWLFDOVLJQLILFDQWHYLGHQFHRISXEOLFDWLRQELDV(JJHU¶V302 
test: p=0.21; Supplemental Figure 1D), however only four studies were included. 303 
For fructose intake (range: 8.5-64.2 g/d) and risk of breast cancer risk, three 304 
studies, including 11,542 cases among 352,627 women were identified.18-20 The 305 
summary RR per 10 g/d was 0.99 (0.96-1.01, I2=14%, pheterogeneity=0.31) (Figure 6A). 306 
There was a suggestion of a non-linear positive association between fructose intake 307 
and breast cancer (pnon-linearity<0.001), with a change of the direction of the association 308 
from amounts of 40 g/d (Figure 6B). We did not observe statistical significant evidence 309 
RISXEOLFDWLRQELDV (JJHU¶V WHVWS 3; Supplemental Figure 1E), however only 310 
three studies were included. 311 
Few studies investigated the associations between other types of sugars, 312 
including sucrose,18, 20 glucose,20 lactose,20 maltose,20 or added sugars18, 19 and risk 313 
of breast cancer. There were not enough studies to conduct meta-analyses on these 314 
specific subtypes of sugars and breast cancer; however, none of the studies have 315 
reported a statistically significant association.  316 
 317 
Discussion 318 
In our dose-response meta-analysis of prospective studies, the risk of breast 319 
cancer was increased by 6% in postmenopausal women for each increment of 10 320 
units/d of GI and no risk increase was observed in premenopausal women, but the 321 
difference was not statistically significant. Overall, a limited number of studies 322 
suggests that the positive association is mainly with ER- and PR- breast cancer 323 
tumours, but no statistically significant result was observed. GL and carbohydrates 324 
were not related to increased risk of breast cancer in pre- and postmenopausal 325 
women. However, higher risk of breast cancer with higher GL and carbohydrate intake 326 
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levels were observed among women with hormone receptor ER- status. The 327 
associations between carbohydrates, GI, GL and pre- and postmenopausal breast 328 
cancer were not modified by BMI.  329 
 Our findings are comparable to findings of previous meta-analyses that 330 
reported a weak increased risk of breast cancer for higher GI levels in postmenopausal 331 
women,23, 25, 26, 28 whereas other meta-analyses did not show.22-24, 27 However, 332 
previous meta-analyses have focused on high vs. low analysis only and to our 333 
knowledge our meta-analysis is the first that investigated the dose-response 334 
association, and explored potential non-linear relations; our findings suggested that 335 
the association was linear. We did not find any evidence of differences between 336 
hormone receptor status for the association on GI and breast cancer, but a suggestive 337 
stronger association was observed for women with hormone receptor negative 338 
tumours. However, the number of studies was limited and more studies are needed 339 
before a conclusion can be drawn.  340 
GL was not related to risk of pre- and postmenopausal breast cancer in our 341 
meta-analysis. The results of previous high vs. low meta-analyses are inconsistent; 342 
some reported a positive association,24, 28 other did not report a significant relation.22, 343 
23, 25-27
 After stratification by hormonal receptor status, the association became 344 
significant for women with ER- and ER-/PR- tumours.  345 
To our knowledge, our meta-analysis is the first on carbohydrates and risk of 346 
breast cancer and we did not detect an association for pre- and post-menopausal 347 
breast cancers. However, similar to GL, a positive association was observed for 348 
women with ER- tumours. We did not detect an association between intake of total 349 
sugar or fructose with breast cancer risk. These findings should be carefully 350 
interpreted because number of studies was limited and we could not perform stratified 351 
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analysis by menopausal status, or hormone receptor status, respectively. Only one 352 
study reported on fructose intake and risk of breast cancer by hormone receptor status 353 
and findings indicated a weak positive association in ER+ tumours [RR (95% CI): 1.06 354 
(0.96-1.18)], and an inverse association for ER- tumours [RR (95% CI): 0.84 (0.67-355 
1.06)], however, findings were not statically significant.20   356 
Our results for the relation of GI and GL with breast cancer are slightly 357 
inconsistent: for women with ER- tumours the association was stronger for GL than 358 
for GI. GI and GL are both measurements of carbohydrate quality. The GI compares 359 
the postprandial glucose response to a fixed amount of 50 grams of the carbohydrates 360 
from different foods with that of a reference food. Because different foods vary 361 
considerably in carbohydrate content, the amount that needs to be eaten to provide 362 
50 grams of carbohydrate differs substantially for different foods. The GL therefore 363 
takes into account both the GI and the total carbohydrate content of the food. The GL 364 
has been shown to be a stronger predictor for postprandial glycemia and insulin 365 
response compared to GI,54, 55 which might explain our observation.   366 
In postmenopausal women, both GI and GL were positively related to ER- 367 
breast cancers, but the association was significant only for GL. It has been indicated 368 
that diets high in GI/GL might be associated with hyperinsulinemia,56, 57 insulin-like 369 
growth factors (IGF-I),58 type 2 diabetes,44 and inflammatory biomarkers,59 which also 370 
play a role in breast cancer carcinogenesis, 6-8, 60, 61 and might be a potential 371 
explanation for the association between GL (and GI) and risk of ER- breast cancers. 372 
The pathological mechanisms remain unclear. A pooled analysis reported that IGF-I 373 
was positively associated with ER+, but not with ER- tumours.58 In contrast to these 374 
findings, our meta-analysis pointed out that the association between diet - related to 375 
glucose metabolism - and breast cancer risk is more relevant in hormone-independent 376 
18 
 
breast cancer, while hormone-dependent breast cancer might be more strongly 377 
influenced by hormonal risk factors.62, 63 However, the number of studies investigating 378 
associations between GI, GL, carbohydrates, and sugars with risk of breast cancer by 379 
hormone receptor status was limited, and more studies are needed to draw a definite 380 
conclusion. 381 
Our meta-analysis has several strengths. First, to our knowledge, this is the first 382 
systematic review and meta-analysis summarizing the evidence on the dose-response 383 
association of carbohydrate, sugar and fructose intake and risk of breast cancer. In 384 
addition, previous meta-analyses on GI, GL and breast cancer only reported high vs. 385 
low analyses and so far, did not o conduct linear or non-linear dose-response 386 
analyses. Second, our meta-analyses included a larger number of women than the 387 
previous studies on this topic (about one million women, including approximately 388 
37,000 breast cancer cases), which enabled us to stratify the analyses by potential 389 
modifying factors, including menopausal status, hormone receptor status, and BMI. 390 
Third, we only included prospective studies in our meta-analysis to avoid recall bias 391 
from retrospective case-control studies, and this may also have led to less potential 392 
for selection bias in our meta-analysis. 393 
Our meta-analysis has some limitations that also need to be considered. First, 394 
a diet high in carbohydrates, GI, GL or sugars may accompany with other behavioural 395 
and dietary factors, such as low physical activity, smoking, overweight and obesity, 396 
excess intake of total energy, and alcohol intake. However, in our meta-analyses 397 
findings did not change substantially in subgroup analyses that included studies with 398 
and without adjustment for these factors. Moreover, we did not find any differences of 399 
associations between normal- and overweight pre- and postmenopausal women. 400 
Second, measurement error of diet cannot be ruled out. The reliability of the GI has 401 
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been discussed in previous studies, which have shown that intra- and inter-individual 402 
variability in glycaemic response for single foods exists,64, 65 and it is not only driven 403 
by methodological factors such as sample size, number of repeat measures and 404 
sampling time, but also by individual biological factors including age, BMI, blood lipids, 405 
CRP, and particularly by glycated haemoglobin (HbA1c) and insulin index.64 In 406 
addition, and FFQs are not specifically designed to measure GI and GL, which might 407 
have attenuated our results. However, positive associations between GI, GL and other 408 
chronic diseases (e.g. type 2 diabetes) were identified using information on GI and GL 409 
from similar databases and similar FFQs.44, 66 Moreover, dietary information was 410 
assessed at baseline and we have no information on change in dietary behaviour over 411 
time, which could have influenced our results. However, because of the prospective 412 
design of the studies any changes in diet after baseline would most likely have tended 413 
to attenuate the observed associations. Finally, our results that hormone receptor 414 
status of the tumours might affect the association between carbohydrates and GL and 415 
risk of breast cancer should be interpreted with caution because of the limited numbers 416 
of studies available. Thus, it is important to investigate whether exogenous hormones, 417 
such as the use of HRT can affect these associations as well and in our meta-analysis, 418 
we could not stratify for HRT use because data was limited. Only one study 419 
investigated the association between GI and risk of breast cancer stratified by HRT 420 
use, and reported a stronger association for HRT users [summary RR (95%CI): 2.15 421 
(1.16-4.00)] compared to never users [summary RR (95%CI): 1.58 (0.79-3.18)] by 422 
comparing high versus low values of GI.13  423 
In conclusion, in our meta-analysis, GI showed a weak positive linear 424 
association with risk of postmenopausal breast cancer, but the difference between 425 
menopausal status was not statistically significant. GL and carbohydrates were 426 
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associated with increased risk of breast cancer only among women with hormone 427 
receptor negative tumours, particularly ER-. Further studies on GI, GL, carbohydrates, 428 
sugar intake and risk of breast cancer, accounting for menopausal status, hormone 429 
receptor status, excess body weight, and HRT use are needed.    430 
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Table 1: Description of the PICOS criteria used in the meta-analysis 
Parameter Inclusion criteria 
Population Women without breast cancer at baseline 
Intervention/exposures 
Dietary intake of carbohydrates, GI, GL, specific types of 
carbohydrates (total and specific sugars, including fructose, sucrose, 
glucose, lactose, maltose and added sugars) 
Comparison  Dose-response relation  
Outcomes Breast cancer  
Type of study 
Prospective studies: cohort, case-cohort and nested case-control 
studies, and follow-up studies of randomized clinical trials 
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Table 2: Study characteristics of prospective studies included in the meta-analysis on intake of carbohydrates, sugars, GI, GL and breast cancer risk 
First Author, 
Year, Country 
Study name, design, age, 
other characteristics   
Study 
size, 
Number 
of cases 
Follow-
up  
Dietary 
assessment 
 
Carbohydrates 
Comparison 
RR (95% CI) 
GI 
Comparison 
RR (95% CI) 
GL 
Comparison 
RR (95% CI) 
Sugars 
Comparison 
RR (95% CI) 
Farvid,17  
2014, 
USA   
1XUVHV¶+HDOWK6WXG\ 
Prospective cohort study, 
(NHS) II, 
27-44 y  
90,488,  
2,833 
20 y 
 
Validated FFQ 
in early 
adulthood,  
137 food items 
59.2 vs 40.6 % of 
energy 
All: 
0.88 (0.78-0.99) 
Premenopausal: 
0.88 (0.75-1.03) 
Postmenopausal: 
0.87 (0.70-1.08) 
 
Converted into 
gram per d 
57.9 vs 49.7 
units/d 
All:  
1.03 (0.91-1.16) 
Premenopausal: 
1.05 (0.90-1.23) 
Postmenopausal: 
1.08 (0.87-1.35) 
BMI <25 (at age 
18y): 
1.04 (0.92-1.18) 
%0,DWDJH
18y): 
1.12 (0.68-1.85) 
ER+/PR+: 
1.09 (0.93-1.28) 
ER-/PR-: 
0.95 (0.69-1.30) 
149 vs 96 units/d 
 
All:  
0.94 (0.83-1.06) 
Premenopausal: 
0.93 (0.79-1.09) 
Postmenopausal: 
0.95 (0.76-1.18) 
BMI <25 (at age 
18y): 
0.94 (0.83-1.06) 
%0,DWDJH
18y): 
1.19 (0.70-2.03) 
 
 
Romieu,16  
2012,  
Europe 
European Prospective 
Investigation into Cancer 
and Nutrition (EPIC) study, 
Prospective cohort study, 
35-70 y 
334,849, 
11,576 
11.5 y Validated 
FFQ, diet 
history, 7-d 
food diary 
(depending on 
the cohort) 
>244.1 vs <185.3 
g/d 
All:  
1.04 (0.96-1.12) 
Premenopausal: 
1.01 (0.87-1.17) 
Postmenopausal: 
1.01 (0.87-1.17) 
ER- 
1.24 (1.02-1.52) 
ER-/PR- 
1.33 (1.05-1.67) 
>58.9 vs <52.7 
units/d 
All:  
1.05 (0.99-1.12) 
Premenopausal: 
1.02 (0.90-1.16) 
Postmenopausal: 
1.07 (0.99-1.17) 
ER- 
1.04 (0.88-1.24) 
ER-/PR- 
1.04 (0.86-1.26) 
>137.8 vs <101.8 
units/d 
All:  
1.07 (1.00-1.14) 
Premenopausal: 
1.04 (0.91-1.20) 
Postmenopausal: 
1.09 (0.99-1.20) 
ER- 
1.16 (0.96-1.41) 
ER-/PR- 
1.17 (0.94-1.46) 
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ER+ 
0.95 (0.86-1.06) 
ER- & postm. 
1.41 (1.05-1.89) 
ER-/PR- & postm. 
1.62 (1.15-2.30) 
ER+ & postm. 
0.98 (0.85-1.13) 
ER-/PR-/ HER2- 
1.26 (0.75-2.11) 
ER-/PR-/ HER2+ 
1.67 (0.93-2.98) 
ER+ 
1.01 (0.93-1.10) 
ER- & postm. 
1.21 (0.93-1.56) 
ER-/PR- & postm. 
1.23 (0.92-1.65) 
ER+ & postm. 
1.01 (0.90-1.14) 
ER-/PR-/ HER2- 
1.03 (0.65-1.65) 
ER-/PR-/ HER2+ 
1.48 (0.87-2.52) 
ER+ 
1.01 (0.93-1.11) 
ER- & postm. 
1.36 (1.02-1.82) 
ER-/PR- & postm. 
1.48 (1.07-2.05) 
ER+ & postm. 
1.00 (0.87-1.14) 
ER-/PR-/ HER2- 
1.35 (0.83-2.19) 
ER-/PR-/ HER2+ 
1.35 (0.83-2.19) 
Tasevska,18  
2012 
USA 
National Institutes of 
Health-American 
Association of Retired 
Persons (NIH-AARP) 
Diet and Health Study, 
Prospective cohort study,  
50-71 years 
179,990, 
4,793 
 
7.2 y Validated 
semi-
quantitative 
FFQ,  
124 food items 
  
 
 Total sugars: 
91.5 vs 38.7 g/1000 
kcal 
0.96 (0.85-1.08) 
Added sugars:  
11.0 vs 2.4 
tsp/1000 kcal 
1.01 (0.91-1.12) 
Total fructose: 
40.6 vs 14.8 g/1000 
kcal 
0.93 (0.84-1.04) 
Sucrose:  
37.5 vs 13.6 g/1000 
kcal 
1.02 (0.93-1.13) 
Shikany,19  
2011,  
USA  
:RPHQ¶V+HDOWK,QLWLDWLYH
(WHI), 
Follow-up of a randomized 
controlled trial and 
prospective cohort study, 
50-79 y, 
postmenopausal 
 
148,767, 
6,098 
8 y Validated 
FFQ,  
122 food items  
 
 
Available CHO: 
>305.7 vs <112.3 
g/d 
All: 
0.95 (0.80-1.14) 
ER+/PR+: 
0.99 (0.77-1.27) 
ER+/PR-: 
>57.0 vs <47.8 
units/d 
All: 
1.01 (0.91-1.12) 
ER+/PR+: 
1.05 (0.90-1.22) 
ER+/PR-: 
1.01 (0.71-1.43) 
>150.4 vs <52.9 
units/d 
All: 
1.08 (0.92-1.29) 
ER+/PR+: 
0.81 (0.63-1.04) 
ER+/PR-: 
0.60 (0.33-1.09) 
Total sugars: 
>155.4 vs <48.5g/d 
1.06 (0.92-1.21) 
Added sugars: 
>85.2 vs <18.1 g/d 
1.01 (0.89-1.16) 
Fructose: 
>35.0 vs <8.5 g/d 
1.07 (0.95-1.21) 
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0.75 (0.42-1.34) 
ER-/PR-: 
1.33 (0.75-2.38) 
ER-/PR-: 
1.07 (0.74-1.52) 
 
ER-/PR-: 
1.68 (0.93-3.02) 
George,29  
2009, 
USA  
National Institutes of 
Health-American 
Association of Retired 
Persons (NIH-AARP) 
Diet and Health Study, 
Prospective cohort study, 
50-71 years 
postmenopausal  
183,535, 
5,478 
6.9 y Validated 
semi-
quantitative 
FFQ,  
124 food items 
 56.6-83.9 vs 33.6-
50.4 units/d 
1.05 (0.97-1.15) 
 
 
135.3-583.7 vs 
4.6-66.9 units/d 
0.96 (0.81-1.12) 
 
Larsson,15  
2009, 
Sweden  
Swedish Mammography 
Cohort (SMC),  
Prospective cohort study,  
mean 54 y, 
Screening program, 
postmenopausal  
 
61,433, 
2,952 
17.4 y Validated 
FFQ,  
67 food items 
YVJG 
All: 
1.09 (0.95-1.25) 
ER+/PR+: 
1.08 (0.88-1.33) 
ER+/PR-: 
1.34 (0.93-1.94) 
ER-/PR-: 
1.14 (0.73-1.79) 
 
YV
units/d 
All: 
1.08 (0.96-1.21) 
ER+/PR+: 
0.89 (0.74-1.06) 
ER+/PR-: 
1.44 (1.06-1.97) 
ER-/PR-: 
1.29 (0.85-1.96) 
 
YV
units/d 
All: 
1.13 (1.00-1.29) 
ER+/PR+: 
0.94 (0.77-1.13) 
ER+/PR-: 
1.81 (1.29-2.53) 
ER-/PR-: 
1.23 (0.79-1.90) 
BMI <25: 
1.26 (1.06-1.50) 
%0, 
1.08 (0.88-1.33) 
BMI <25& 
ER+/PR- 
2.03 (1.35-3.06) 
%0,	
ER+/PR- 
1.80 (0.92-3.53) 
 
 
Wen,14  
2009, 
China 
6KDQJDL:RPHQ¶V+HDOWK
Study (SWHS), 
Prospective cohort study,  
40-70 y 
 
73.328, 
616 
7.4 y Validated 
FFQ,  
77 food items 
 
343.5 vs 257.5 g/d 
All: 
1.22 (0.94-1.58) 
Premenopausal: 
2.01 (1.26-3.19) 
76.8 vs 63.9 
units/d 
All: 
1.03 (0.79-1.34) 
Premenopausal: 
239.4 vs 163.8 
units/d 
All: 
1.07 (0.82-1.39) 
Premenopausal: 
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Postmenopausal: 
0.98 (0.72-1.34) 
BMI <25: 
1.09 (0.90-1.31) 
%0, 
1.06 (0.85-1.31) 
BMI <25 & prem.: 
1.54 (1.10-2.16) 
%0,	SUHP 
1.71 (1.05-2.80) 
1.19 (0.73-1.94) 
Postmenopausal: 
0.96 (0.70-1.31) 
 
1.53 (0.96-2.45) 
Postmenopausal: 
0.91 (0.67-1.25) 
 
Lajous,33  
2008, 
France 
E3N- European 
Prospective Investigation 
into Cancer and Nutrition 
(EPIC) study -France, 
Prospective cohort study,  
42-72 y, 
postmenopausal 
1,812, 
62,739 
9 y Dietary history BMI <25 & postm.: 
1.04 (0.89-1.20) 
%0,	SRVWP.: 
1.07 (0.77-1.49) 
only included in 
subgroups analysis 
BMI <25 & postm.: 
1.09 (0.93-1.28) 
%0,	SRVWP.: 
1.35 (1.00-1.82) 
only included in 
subgroups analysis 
BMI <25 & postm.: 
1.08 (0.92-1.28) 
%0,	SRVWP.: 
1.22 (0.90-1.67) 
only included in 
subgroups analysis 
 
Sieri,51  
2007,  
Italy 
Hormones and Diet in the 
Etiology of Breast Cancer" 
(ORDET) study, 
Prospective cohort study,  
34-70 y,  
 
8,926, 
289 
 
11.5 y Semi-
quantitative 
FFQ, 107 food 
items 
Not included in 
meta-analysis: 
CHO reported per 
5 %energy 
 
>57.5 vs <53.5 
units/d 
All:  
1.57 (1.04-2.36) 
Premenopausal: 
1.82 (1.01-3.27) 
Postmenopausal: 
1.12 (0.62-2.02) 
BMI <25: 
2.22 (1.18-4.19) 
%0, 
1.11 (0.64-1.94) 
>133.7vs <103.2 
units/d 
All:  
2.53 (1.54-4.16) 
Premenopausal: 
3.89 (1.81-8.34) 
Postmenopausal: 
1.67 (0.80-3.46) 
BMI <25: 
5.79 (2.60-12.9) 
%0, 
1.31 (0.66-2.61) 
 
Nielsen,20  
2005, 
Denmark 
Diet, Cancer and Health 
(DCH) study, 
Prospective cohort study,  
50-65 y, 
postmenopausal 
23,870, 
634 
6.6 y Validated 
FFQ, 192 food 
items 
Not included for 
CHO: overlap with 
Romieu, 2012 
Not included for 
GI: overlap with 
Romieu, 2012 
 
Not included for 
GL: overlap with 
Romieu, 2012 
Glucose: 
per 50 g/d 
All:  
1.06 (0.79-1.42) 
ER+: 
1.05 (0.91-1.21) 
ER-: 
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0.86 (0.64-1.16) 
Fructose 
per 10 g/d 
All:  
0.99 (0.81-1.20) 
ER+: 
1.06 (0.96-1.18) 
ER-: 
0.84 (0.67-1.06) 
Sucrose 
per 10 g/d 
All:  
1.01 (0.94-1.08) 
ER+: 
1.01 (0.95-1.07) 
ER-: 
1.05 (0.94-1.16) 
Maltose 
per 2 g/d 
All:  
1.02 (0.88-1.18) 
ER+: 
1.04 (0.90-1.20) 
ER-: 
1.03 (0.78-1.38) 
Lactose 
per 10 g/d 
All:  
1.04 (0.98-1.10) 
ER+: 
1.04 (0.97-1.11) 
ER-: 
1.07 (0.95-1.22) 
Silvera,13  
2005,  
Canada  
Canadian National Breast 
Screening Study (CNBSS), 
Prospective cohort study,   
40-59y, 
Screening program  
49,111, 
1,450 
16.6 y Validated 
FFQ, 69 food 
items  
 
>249 vs <143 g/d 
All: 
0.93 (0.70-1.22) 
 
>96 vs <60 units/d 
All:  
0.88 (0.63-1.22) 
Premenopausal: 
0.78 (0.52-1.16) 
Postmenopausal: 
 >175 vs <119 
units/d 
All:  
0.95 (0.79-1.14) 
Premenopausal: 
0.96 (0.76-1.22) 
Total sugars: 
>103 vs <52 g/d 
All: 
0.88 (0.70-1.12) 
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1.87 (1.18-2.97) 
BMI <25 & prem.: 
0.89 (0.54-1.45) 
%0,	SUHP 
0.62 (0.32-1.23) 
BMI <25 & postm.: 
1.99 (1.06-9.72) 
%0,	SRVWP 
1.57 (0.78-3.13) 
Postmenopausal: 
1.08 (0.82-1.41) 
BMI <25 & prem.: 
1.01 (0.76-1.35) 
%0,	SUHP 
0.85 (0.55-1.31) 
BMI <25 & postm.: 
0.97 (0.68-1.39) 
%0,	SRVWP 
1.22 (0.82-1.82) 
Holmes,12  
2004, 
USA 
1XUVHV¶+HDOWK6WXG\
(NHS),  
Prospective cohort study,  
35-55 y, 
Registered nurses 
88,678, 
4,092 
18 y Validated 
semi-
quantitative 
FFQ, 61 food 
items  
 
 
240 vs 159 g/d 
All:  
0.97 (0.87-1.08) 
Premenopausal: 
0.98 (0.78-1.23) 
Postmenopausal: 
0.96 (0.84-1.09) 
BMI <25 & prem.: 
1.20 (0.89-1.61) 
%0,	SUHP 
0.72 (0.48-1.07) 
BMI <25 & postm.: 
0.95 (0.78-1.15) 
%0,	SRVWP 
0.96 (0.80-1.17) 
81 vs <9 units/d 
All:  
1.08 (0.97-1.19) 
Premenopausal: 
1.02 (0.82-1.28) 
Postmenopausal: 
1.15 (1.02-1.30) 
BMI <25 & prem.: 
1.06 (0.79-1.42) 
%0,	SUHP 
0.83 (0.57-1.22) 
BMI <25 & postm.: 
1.28 (1.08-1.53) 
%0,	SRVWP 
1.05 (0.87-1.26) 
186 vs 116 units/d 
All:  
0.98 (0.87-1.11) 
Premenopausal: 
0.87 (0.70-1.12) 
Postmenopausal: 
1.03 (0.90-1.16) 
BMI <25 & prem.: 
1.01 (0.75-1.35) 
%0,	SUHP 
0.68 (0.45-1.03) 
BMI <25 & postm.: 
1.06 (0.87-1.28) 
%0,	SRVWP 
0.97 (0.80-1.18) 
 
Higginbotham,30  
2004,  
USA 
:RPHQ¶VKHDOWKVWXG\
(WHS),  
Prospective cohort study 
(based on randomized 
controlled trial), 
\ 
38,446, 
897 
6.8 y Validated 
semi-
quantitative 
FFQ, 131 food 
items 
 Q5 vs Q1 (no 
quantity)  
Not included in  
dose-response 
meta-analysis   
143 vs. 92 units/d 
All:  
1.01 (0.76-1.35) 
Premenopausal: 
1.27 (0.79-2.03) 
Postmenopausal: 
0.90 (0.63-1.31) 
 
Jonas,52  
2003, 
USA 
Cancer Prevention Study 
(CPS) II Nutrition Cohort,  
Prospective cohort study,  
70,888, 
1,442 
 
5 y Validated 
semi-
quantitative 
 85 vs 65 units/d  
1.03 (0.87-1.22) 
147 vs 83 units/d 
0.90 (0.76-1.08) 
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50-74 y, 
postmenopausal 
FFQ, 68 food 
items 
  
Sieri,21  
2002, 
Italy 
"Hormones and Diet in the 
Etiology of Breast Cancer" 
(ORDET) study,  
Nested case-control study, 
41-70 y, 
postmenopausal 
214 
controls, 
56 cases  
5.5 y semi-
quantitative 
FFQ, 107 food 
items 
217.6-303.4 vs 
<190.2 g/d  
0.73 (0.33±1.59) 
 
  Total sugars: 
72.9±141.0 g vs. 
<54.3 g/d 
0.34 (0.11±1.03) 
Kushi,34  
1995, 
USA 
Iowa Women's Health 
Study (IWHS),  
Prospective cohort study,  
55-69 y, 
postmenopausal  
34,388, 
262 
6 y Validated 
semi-
quantitative 
FFQ, 127 food 
items (same 
used 1984 in 
Nurses Health 
Study) 
YVJd 
ER+/PR+: 
0.79 (0.60-0.79) 
ER+/PR-: 
0.78 (0.44-1.39) 
ER-/PR+: 
3.82(0.76-19.19) 
ER-/PR-: 
0.60 (0.31-1.14) 
Unknown  
0.98 (0.72-1.35) 
   
Barrett-Connor,11  
1993, 
USA 
Rancho Bernardo, 
Prospective cohort study,  
40-79 y 
590, 
15 
 
15 y 24h recall per 66 g/d 
1.93 (1.18-3.16) 
   
Kushi,10  
1992 
USA 
Iowa Women's Health 
Study (IWHS),  
Prospective cohort study, 
55-69 y, 
postmenopausal 
34,388, 
459 
4 y Validated 
semi-
quantitative 
FFQ, 127 food 
items (same 
used 1984 in 
Nurses Health 
Study) 
YVJd 
1.16 (0.72-1.86) 
   
Knekt,9  
1990, 
Finland  
Social Insurance 
,QVWLWXWLRQ¶V0RELOH&OLQLF
Health Examination 
Survey,  
Prospective cohort study,  
20-69 y 
3,988, 
54 
20 y Dietary history 
method 
 
YVJd 
0.40 (0.16±1.00) 
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Table 3. Summary relative risks (RR) and 95% confidence intervals (95% CI) of dose-response meta-analyses of carbohydrates, GI, GL and breast cancer by subgroups. 
  
Carbohydrates (per 50 g/d) GI (per 10 units/d) GL (per 50 units/d) 
 
Summary RR 
(95% CI) n 
I2 
(%) pwithina pbetweenb 
Summary RR 
(95% CI) n 
I2 
(%) pwithina pbetweenb 
Summary RR 
(95% CI) n 
I2 
(%) pwithina pbetweenb 
All studies 1.00 (0.96-1.05) 11 57.3 .009 - 1.04 (1.00-1.07) 10 27.2 .194 - 1.01 (0.98-1.04) 11 42.7 .065  
Menopausal status 
    
.999 
    
.150 
    
.671 
 Premenopausal 1.03 (0.91-1.17) 4 76.1 .006 1.01 (0.93-1.10) 6 34.0 .181 1.07 (0.92-1.24) 7 72.0 .002 
 Postmenopausal 1.00 (0.95-1.06) 9 44.9 .069 1.06 (1.02-1.10) 10 19.2 .266 1.02 (0.99-1.06) 11 3.5 .409 
Time of assessment of premenopausal statusc 
  
.444 
    
.502 
 
   
.968 
 At exposure  0.96 (0.90-1.02) 2 0 .400 0.99 (0.89-1.11) 4 42.9 .154 1.04 (0.88-1.23) 5 66.9 .017 
 At cancer diagnosis  1.22 (0.75-1.98) 2 89.7 .002 1.08 (0.89-1.29) 2 18.1 .269 1.15 (0.70-1.88) 2 89.1 .002 
Hormone receptor status  
   
 
    
 
     
All 
    
 
    
 
     
estrogen receptor (ER) 
    
.029 
    
.882 
    
.055 
 
 ER+ 0.97 (0.93-1.01) 4 17.7 .302 1.04 (0.97-1.12) 4  .911 0.99 (0.95-1.02) 3 53.6 .116 
 
 ER- 1.11 (1.02-1.21) 4 0 .820 1.03 (0.90-1.18) 4  .870 1.20 (1.05-1.38) 3 0 .976 
progesterone receptor (PR) 
   
.427 
    
.849 
.849   
 
.182 
 
 PR+ 0.97 (0.92-1.03) 3 0 .525 1.02 (0.91-1.14) 3  .234 0.91 (0.83-1.00) 2 0 .487 
 
 PR- 1.04 (0.90-1.21) 4 63.8 .040 1.03 (0.89-1.20) 4  .577 1.05 (0.96-1.14) 3 72.9 .025 
combinations     
.379 
    
.200 
 
 
  
.591 
 
 ER+/PR+ 0.93 (0.81-1.06) 3 73.2 .024 1.02 (0.91-1.14) 3  .234 0.91 (0.83-1.00) 2 0 .487 
 
 ER+/PR- 1.05 (0.78-1.40) 3 62.2 .071 1.29 (0.96-1.73) 2  .188 1.16 (0.54-2.51) 2 92.8 .000 
 
 ER-/PR- 1.09 (0.96-1.24) 4 32.5 .218 1.01 (0.88-1.17) 4  .822 1.19 (1.02-1.38) 3 0 .987 
 
 ER-/PR+ 2.99 (0.75-11.89) 1 - - - -  - - - - - 
Postmenopausal d 
  
    
   
 
    
 
estrogen receptor (ER) 
    
.047 
    
.311 
    
.046 
 
 ER+ 0.98 (0.93-1.04) 4 23.8 .269 1.02 (0.93-1.13) 3 0 .938 0.99 (0.95-1.03) 3 53.8 .115 
 
 ER- 1.13 (1.02-1.25) 4 0 .530 1.16 (0.96-1.40) 3 0 .864 1.28 (1.08-1.52) 3 0 .589 
progesterone receptor (PR) 
   
.464 
    
.353 
   
 
.292 
 
 PR+ 0.97 (0.92-1.03) 3 0 .525 0.99 (0.85-1.15) 2 48.5 .164 0.91 (0.83-1.00) 2 0 .487 
 
 PR- 1.06 (0.86-1.31) 4 70.6 .017 1.19 (0.92-1.54) 2 0 .579 1.08 (0.96-1.21) 3 82.6 .003 
combinations     
.391 
    
.214 
 
 
  
.503 
 
 ER+/PR+ 0.93 (0.81-1.06) 3 73.2 .024 0.99 (0.85-1.15) 2 48.5 .164 0.91 (0.95-1.03) 2 0 .487 
 
 ER+/PR- 1.05 (0.78-1.40) 3 62.2 .071 1.29 (0.96-1.73) 2 42.2 .188 1.16 (0.54-2.51) 2 92.8 .000 
 
 ER-/PR- 1.10 (0.91-1.34) 4 53.9 .089 1.15 (0.94-1.39) 3 0 .950 1.29 (1.08-1.54) 3 0 .494 
 
 ER-/PR+ 2.99 (0.75-11.89) 1 - - - - - -  - - - - 
BMI, kg/m² 
    
 
    
 
     
All 
    
.315 
    
.644 
    
.985 
 < 25 1.02 (0.96-1.08) 3 0 .803 1.08 (0.99-1.17) 5 52.5 .077 1.02 (0.99-1.04) 6 80.7 .000 
  0.97 (0.90-1.04) 3 0 .509 1.03 (0.97-1.11) 5 0 .442 1.01 (0.99-1.02) 6 0 .515 
38 
 
Premenopausal women 
    
.703 
    
.323 
    
.939 
 < 25 1.11 (0.94-1.32) 2 0 .326 0.98 (0.89-1.08) 2 0 .472 0.99 (0.86-1.15) 2 0 .579 
  1.06 (0.55-2.02) 2 80.4 .024 0.88 (0.97-1.20) 2 0 .849 0.79 (0.65-0.97) 2 0 .325 
Postmenopausal women  
   
.839 
    
.705 
    
.942 
 < 25 1.01 (0.94-1.07) 2 0 .539 1.15 (1.01-1.32) 3 71.9 .029 1.01 (0.99-1.03) 4 39.9 .172 
  0.99 (0.91-1.09) 2 0 .725 1.11 (1.02-1.20) 3 0 .683 1.01 (1.00-1.03) 4 0 .394 
Geographic area 
    
.707 
    
.456 
    
.414  Europe 0.94 (0.80-1.10) 4 72.9 .011 1.07 (0.99-1.17) 3 27.2 .194 1.16 (0.96-1.40) 3 82.4 .003 
 North America 0.99 (0.94-1.04) 6 51.9 .605 1.02 (0.98-1.06) 6 20.4 .280 1.00 (0.99-1.01) 7 0 .820 
 Asia-Pacific 1.07 (0.92-1.25) 1 - - 0.97 (0.81-1.18) 1 - - 1.05 (0.89-1.24) 1 - - 
Assessment of GI and GL 
  
 
- 
    
.767 
    
.991  Glucose - - - - 1.03 (0.96-1.10) 5 23.4 .265 1.02 (0.93-1.11) 6 61.9 .022 
 White Bread - - - - 1.05 (1.00-1.11) 3 3.4 .355 1.02 (0.96-1.08) 3 42.7 .159 
 Glucose/ white bread - - - - 1.02 (0.94-1.11) 2 76.9 .037 1.01 (0.97-1.06) 2 0 .501 
Duration of follow-up 
    
.675 
            
.547 
 
   
.825 
 <10 years of follow-up 1.00 (0.96-1.04) 3 0 .509 1.02 (0.97-1.07) 4 0 .642 1.00 (0.96-1.05) 5 0 .732 
 \HDUVRIIROORZ-up 0.99 (0.93-1.06) 8 68.1 .003 1.05 (0.99-1.11) 6 51.3 .068 1.02 (0.96-1.07) 6 67.6 .009 
Number of cases  
    
.925 
    
.056 
 
   
.984 
 <1500 1.00 (0.84-1.19) 6 71.0 .004 1.00 (0.93-1.07) 4 36.2 .195 1.04 (0.91-1.19) 5 63.5 .027 
  1.00 (0.96-1.03) 5 34.6 .191 1.06 (1.02-1.09) 6 0 .753 1.01 (0.98-1.04) 6 22.8 .263 
BMI, body mass index; CI, confidence interval; ER, oestrogen receptor; GI, glycemic index; GL, glycemic load; n, number of studies; PR, progesterone receptor; RR, relative risk 
a pwithin, p for heterogeneity within each subgroup 
b pbetween, p for heterogeneity between subgroups with meta-regression 
c
 only among studies including premenopausal women  
d
 for premenopausal women: no data available  
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Figure 1: Flow chart of study selection: search period June 1st 2008-April 30th 2015. 
Figure 2: Intake of carbohydrates and breast cancer. (A) Dose-response analysis per 50 g/day 
for any breast cancer, (B) by menopausal status, and (C) non-linear dose-response analysis. 
Figure 3: Glycemic index and breast cancer. (A) Dose-response analysis per 10 units/day for 
any breast cancer, (B) by menopausal status, and (C) non-linear dose-response analysis. 
Figure 4: Glycemic load and breast cancer. (A) Dose-response analysis per 50 g/day for any 
breast cancer, (B) by menopausal status, and (C) non-linear dose-response analysis. 
Figure 5: Intake of total sugars and breast cancer. (A) Dose-response analysis per 10 g/day for 
any breast cancer, and (B) non-linear dose-response analysis. 
Figure 6: Intake of fructose and breast cancer. (A) Dose-response analysis per 10 g/day for any 
breast cancer, and (B) non-linear dose-response analysis. 
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Figure 1 
1 541 publications excluded: 
549 reviews/no original data  
116 meta-analyses 
78 letter/editorial/commentary  
39 no measure of association  
257 no exposure of interest 
104 no outcome of interest 
344 case-control studies 
54 other study designs 
34 052 publications excluded: 
title and abstract not relevant  
1 885 publications retrieved and 
assessed for inclusion 
35 937 potentially relevant 
publications 
556 additional publications: 
from 2008 SLR and through 
handsearch 
 
900 publications included in the review: 
871 with cohort, case-cohort or nested case-  
       control design 
11 from randomised controlled trials 
18 pooled analyses 
19 publications from 14 studies included in 
the meta-analysis  
11 publication on carbohydrates (+ 2 publications    
     for subgroup analysis) 
10 publication on GI (+ 1 publications for    
     subgroup analysis) 
11 publication on GL (+ 1 publications for    
     subgroup analysis) 
4 publications on total sugars 
3 publications on fructose 
31 publications on carbohydrates, GI, GL, 
sugars and breast cancer 
12 publications excluded: 
5 duplicate studies 
5 insufficient information on exposure  
2 studies in adolescence 
869 publications excluded: 
exposures other than carbohydrates, 
GI, GL or sugars  
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Figure 2  
 
 
Overall  (I-squared = 57.3%, p = 0.009)
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0.93 (0.85, 1.02)
0.99 (0.91, 1.07)
1.59 (1.20, 2.10)
0.97 (0.85, 1.11)
1.03 (0.91, 1.17)
0.95 (0.85, 1.07)
0.98 (0.90, 1.07)
1.00 (0.96, 1.04)
1.10 (0.96, 1.25)
0.98 (0.83, 1.14)
0.99 (0.92, 1.07)
0.60 (0.36, 0.98)
1.65 (1.13, 2.40)
1.13 (0.83, 1.53)
1.00 (0.95, 1.06)
increment RR (95% CI)
per 50 g/day
30.22
31.07
12.94
25.77
100.00
12.28
17.53
26.48
10.62
8.11
19.36
1.08
1.85
2.68
100.00
Weight
%
  1.5 1.5
(A) Carbohydrates, dose-response per 50 g/day for any breast cancer 
(B) Carbohydrates, dose-response per 50 g/day by menopausal status 
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(C) Carbohydrates, non-linear dose-response 
p for non-linearity: 0.024; n=10 studies 
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Overall  (I-squared = 27.2%, p = 0.194)
Wen
Shikany
Author
Holmes
Jonas
Sieri
Silvera
George
Romieu
Farvid
Larsson
2009
2011
Year
2004
2003
2007
2005
2009
2012
2015
2009
SWHS
WHI
Cohort
NHS
CPS II
ORDET
CNBSS
NIH-AARP
EPIC
NHS II
SMC
1.04 (1.00, 1.07)
0.97 (0.81, 1.18)
0.99 (0.89, 1.10)
increment RR (95% CI)
1.10 (1.01, 1.20)
1.01 (0.94, 1.09)
1.93 (1.01, 3.69)
per
0.98 (0.92, 1.04)
1.07 (0.98, 1.16)
1.06 (1.01, 1.12)
10 units/day
1.03 (0.90, 1.18)
1.07 (0.97, 1.19)
100.00
3.03
8.51
Weight
10.52
13.52
0.28
17.59
11.75
20.88
%
5.34
8.59
  1.5 1.5
(A) Glycemic index, dose-response per 10 units/day for any breast cancer 
Figure 3
.
.
Premenopausal
Farvid
Romieu
Wen
Sieri
Silvera
Holmes
Subtotal  (I-squared = 34.0%, p = 0.181)
Postmenopausal
Farvid
Romieu
Shikany
George
Larsson
Wen
Sieri
Silvera
Holmes
Jonas
Subtotal  (I-squared = 19.2%, p = 0.266)
Author
2015
2012
2009
2007
2005
2004
2015
2012
2011
2009
2009
2009
2007
2005
2004
2003
Year
NHS II
EPIC
SWHS
ORDET
CNBSS
NHS
NHS II
EPIC
WHI
NIH-AARP
SMC
SWHS
ORDET
CNBSS
NHS
CPS II
Cohort
1.08 (0.91, 1.29)
0.99 (0.87, 1.13)
1.26 (0.90, 1.78)
2.15 (0.84, 5.47)
0.93 (0.85, 1.02)
1.02 (0.86, 1.21)
1.01 (0.93, 1.10)
1.02 (0.80, 1.30)
1.08 (0.99, 1.18)
0.99 (0.89, 1.10)
1.07 (0.98, 1.16)
1.07 (0.97, 1.19)
0.88 (0.70, 1.10)
1.50 (0.58, 3.86)
1.16 (1.04, 1.28)
1.12 (1.02, 1.23)
1.01 (0.94, 1.09)
1.06 (1.02, 1.10)
increment RR (95% CI)
10 units/day
per
16.79
24.17
5.75
0.86
34.86
17.57
100.00
2.48
14.26
11.17
15.47
11.27
2.83
0.17
11.52
13.01
17.83
100.00
Weight
%
  1.5 1.5
(B) Glycemic index, dose-response per 10 units/day by menopausal status 
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p for non-linearity: 0.322; n=10 studies 
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(C) Glycemic index, non-linear dose-response 
p for non-linearity: 0.322; n=10 studies 
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Overall  (I-squared = 42.7%, p = 0.065)
Silvera
Jonas
Shikany
Romieu
Author
Sieri
Holmes
Higginbotham
Wen
George
Farvid
Larsson
2005
2003
2011
2012
Year
2007
2004
2004
2009
2009
2015
2009
CNBSS
CPS II
WHI
EPIC
Cohort
ORDET
NHS
WHS
SWHS
NIH-AARP
NHS II
SMC
1.01 (0.98, 1.04)
50 units/day
0.98 (0.88, 1.09)
0.97 (0.86, 1.10)
1.04 (0.96, 1.13)
1.02 (0.97, 1.07)
increment RR (95% CI)
2.35 (1.39, 3.96)
per
1.00 (0.99, 1.01)
0.97 (0.75, 1.25)
1.05 (0.89, 1.24)
0.98 (0.91, 1.05)
0.95 (0.85, 1.05)
1.12 (1.00, 1.26)
100.00
%
6.66
5.55
10.84
17.10
Weight
0.37
28.85
1.49
3.48
12.81
6.87
5.99
  1.5 1.5
(A) Glycemic load, dose-response per 50 units/day for any breast cancer 
.
.
Premenopausal
Farvid
Romieu
Wen
Sieri
Silvera
Higginbotham
Holmes
Subtotal  (I-squared = 72.0%, p = 0.002)
Postmenopausal
Farvid
Romieu
Shikany
George
Larsson
Wen
Sieri
Silvera
Higginbotham
Holmes
Jonas
Subtotal  (I-squared = 3.5%, p = 0.409)
Author
2015
2012
2009
2007
2005
2004
2004
2015
2012
2011
2009
2009
2009
2007
2005
2004
2004
2003
Year
NHS II
EPIC
SWHS
ORDET
CNBSS
WHS
NHS
NHS II
EPIC
WHI
NIH-AARP
SMC
SWHS
ORDET
CNBSS
WHS
NHS
CPS II
Cohort
0.94 (0.81, 1.08)
1.01 (0.89, 1.14)
1.50 (1.13, 2.00)
3.41 (1.57, 7.41)
0.93 (0.79, 1.11)
1.26 (0.82, 1.94)
0.91 (0.78, 1.06)
1.07 (0.92, 1.24)
0.98 (0.81, 1.19)
1.07 (0.98, 1.17)
1.04 (0.96, 1.13)
0.98 (0.91, 1.05)
1.12 (1.00, 1.26)
0.90 (0.74, 1.09)
1.57 (0.72, 3.44)
1.06 (0.87, 1.28)
0.85 (0.61, 1.17)
1.03 (0.95, 1.12)
0.97 (0.86, 1.10)
1.02 (0.99, 1.06)
increment RR (95% CI)
50 units/day
per
19.38
20.02
12.58
3.22
17.98
8.06
18.76
100.00
3.25
14.74
18.38
23.72
8.43
3.24
0.20
3.18
1.13
16.02
7.70
100.00
Weight
%
  1.5 1.5
  
Figure 4 
(B) Glycemic load, dose-response per 50 units/day by menopausal status 
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(C) Glycemic load, non-linear dose-response 
p for non-linearity: 0.040; n=11 studies 
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Overall  (I-squared = 52.6%, p = 0.097)
Sieri
Tasevska
Author
Silvera
Shikany
2002
2012
Year
2005
2011
ORDET
NIH-AARP
Cohort
CNBSS
WHI
0.99 (0.98, 1.01)
0.85 (0.71, 1.02)
per 10 g/day
0.99 (0.98, 1.00)
increment RR (95% CI)
0.99 (0.96, 1.02)
1.00 (0.99, 1.02)
100.00
0.70
%
39.62
Weight
17.46
42.22
  1.5 1.5
(A) Total sugar, dose-response per 10 g/day for any breast cancer 
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Best fitting cubic spline
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(B) Total sugar, non-linear dose-response 
p for non-linearity: 0.236; n=4 studies 
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p for non-linearity: <0.001; n=3 studies 
Figure 6 
Overall  (I-squared = 14.2%, p = 0.312)
Nielsen
Shikany
Author
Tasevska
2005
2011
Year
2012
DCH
WHI
Cohort
NIH-AARP
0.99 (0.96, 1.01)
0.99 (0.81, 1.20)
1.02 (0.97, 1.06)
per 10 g/day
increment RR (95% CI)
0.98 (0.95, 1.00)
100.00
1.67
30.76
%
Weight
67.56
  1.8 1.5
(A) Fructose, dose-response per 10 g/day for any breast cancer 
(B) Fructose, non-linear dose-response 
